YourBio Health
- Industry
- Medical Devices
- Founded Year
- 2007
- Headquarters
- 200 Boston Avenue, Suite 3700, Medford, MA 02155, United States
- Employee Count
- 38
Key People
- Paul Owen - President, Chief Executive Officer, Board Member
- Michael Mina - Chief Scientific Officer
- Chet Robson - Chief Medical Officer
- Thomas Briggs - Chief Commercial Officer
- Ignacio Martinez - Executive Chairman, General Partner at Flagship Pioneering
- Wendy Lane - Board Member
- Christine Heenan - Board Member, Executive Partner at Flagship Pioneering
- Thomas Cahill - Board Member, Founder and Managing Partner at Newpath Partners LLC
- Mark Stevenson - Board Member, Senior Partner at Flagship Pioneering
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned professionals with extensive experience in medical devices and healthcare.
Paul Owen, the CEO, has over 25 years of experience in corporate leadership and strategic planning within the healthcare sector. Other key members, such as Michael Mina and Chet Robson, bring significant scientific and medical expertise, enhancing the company's capability to develop and commercialize medical devices.
- Clinical Need
-
Aspect: Very Strong
Summary: The TAP device addresses a significant need for painless and convenient blood collection.
Traditional blood collection methods can be painful and inconvenient, leading to patient reluctance. YourBio Health's TAP device offers a virtually painless alternative, which is particularly beneficial for patients requiring frequent blood tests, such as those with chronic conditions.
- Competition
-
Aspect: Somewhat crowded
Summary: The market has several players offering similar blood collection technologies.
Competitors like Tasso and HemaXis also offer innovative blood collection solutions. YourBio Health's success will depend on its ability to demonstrate superior efficacy, user experience, and establish strong partnerships with healthcare providers.
- Technical Challenge
-
Aspect: Predictable
Summary: The technology is well-developed with manageable technical risks.
The TAP device utilizes proprietary HALO technology, which has been developed and refined over several years. This maturity in technology suggests that the company has overcome major technical hurdles, allowing focus on scaling and commercialization.
- Patent
-
Aspect: Strong
Summary: The company holds robust patents protecting its technology.
YourBio Health's proprietary HALO technology and TAP device are protected by patents, which safeguard against direct competition and can serve as valuable assets in strategic partnerships or licensing deals.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
With $21 million raised in 2021 led by Flagship Pioneering and Newpath Partners, YourBio Health has the financial resources to accelerate growth and support new product launches. This funding enhances the company's ability to invest in R&D, regulatory approvals, and commercialization strategies.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company has achieved key regulatory milestones, including CE Mark certification.
In 2023, YourBio Health received CE Mark certification for its TAP Micro Select device, allowing commercialization in European markets. This achievement demonstrates the company's commitment to meeting stringent regulatory standards, which is essential for gaining trust and adoption in the healthcare industry.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.7
- Segment CAGR
- 5.4%
- Market Segment
- Diagnostic Devices
- Market Sub Segment
- Blood Collection Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
YourBio Health's innovative TAP device addresses a significant clinical need for painless blood collection, supported by a strong team and solid funding, positioning the company well in a competitive market.